Rational drug design or the pathology of amyloid diseases are only two problems whose solution requires a detailed understanding of the relation between chemical composition and structure (and function) of proteins. The present project describes attempts to explore this relationship through computer simulations. The goal is to understand the folding and interaction of proteins solely from the physical forces between the atoms within a protein, and between the protein and the surrounding environment. Extending previous work and relying on algorithms developed in his group, the PI aims at deriving models that describe the fundamental processes of protein folding, aggregation and interaction in a cell. As an example, the PI will study in silico the mechanism by that two proteins, the 64- residue Chymotrypsin Inhibitor 2 and the 93-residue protein TOP7, fold into their specific shape. This is in itself a daring computational task that will require further algorithmic advances and implementation in massively parallel software. Simulating these molecules the PI will not push computer simulations beyond its present limits, and establish rules that describe folding in small proteins. Knowledge of such rules will pave the way to more efficient ways of drug design. In a second line of research the PI goes beyond single proteins and studies the interaction between multiple A chains and their subsequent oligomerization. He will investigate what factors favor oligomeric species over monomeric states, and the effect of point mutations and metal ions on the stability of the oligomers. As A aggregates are connected with the neuropathology of Alzheimer's disease this study will contribute to the developing understanding of the biogenesis of this disease.
Folding, Misfolding and Aggregation of Small Proteins Project Narrative Computer simulations are proposed to study the process by that proteins fold into their biologically active form, and the conditions under that these molecules misfold and subsequently aggregate. This will contribute to the developing understanding of the biogenesis of diseases related to misfolding and aggregation, and could lead to more efficient ways of drug design.
|Alred, Erik J; Phillips, Malachi; Berhanu, Workalemahu M et al. (2015) On the lack of polymorphism in AÎ²-peptide aggregates derived from patient brains. Protein Sci 24:923-35|
|YaÅŸar, Fatih; Jiang, Ping; Hansmann, Ulrich H E (2014) Multicanonical Molecular Dynamics Simulations of the N-terminal Domain of Protein L9. Europhys Lett 105:30008|
|Berhanu, Workalemahu M; Hansmann, Ulrich H E (2014) Inter-species cross-seeding: stability and assembly of rat-human amylin aggregates. PLoS One 9:e97051|
|YaÅŸar, Fatih; Sieradzan, Adam K; Hansmann, Ulrich H E (2014) Folding and self-assembly of a small heterotetramer. J Chem Phys 140:105103|
|Berhanu, Workalemahu M; Hansmann, Ulrich H E (2014) Stability of amyloid oligomers. Adv Protein Chem Struct Biol 96:113-41|
|Alred, Erik J; Scheele, Emily G; Berhanu, Workalemahu M et al. (2014) Stability of Iowa mutant and wild type AÎ²-peptide aggregates. J Chem Phys 141:175101|
|Berhanu, W M; Jiang, P; Hansmann, U H E (2013) Folding and association of a homotetrameric protein complex in an all-atom Go model. Phys Rev E Stat Nonlin Soft Matter Phys 87:014701|
|Bernhardt, Nathan A; Berhanu, Workalemahu M; Hansmann, Ulrich H E (2013) Mutations and seeding of amylin fibril-like oligomers. J Phys Chem B 117:16076-85|
|Berhanu, Workalemahu M; YaÅŸar, Fatih; Hansmann, Ulrich H E (2013) In silico cross seeding of AÎ² and amylin fibril-like oligomers. ACS Chem Neurosci 4:1488-500|
|Berhanu, Workalemahu M; Hansmann, Ulrich H E (2013) The stability of cylindrin *-barrel amyloid oligomer models-a molecular dynamics study. Proteins 81:1542-55|
Showing the most recent 10 out of 35 publications